Tenax Therapeutics (TENX) News Today → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free TENX Stock Alerts $3.48 -0.12 (-3.33%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineTENX: 2023 Financial Resultsfinance.yahoo.com - April 9 at 12:56 PMTenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”globenewswire.com - April 9 at 8:30 AMTenax Therapeutics: Q4 Earnings Insightsbenzinga.com - March 28 at 10:25 PMTENX Stock Earnings: Tenax Therapeutics Misses EPS for Q4 2023msn.com - March 28 at 10:25 PMTenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Resultsglobenewswire.com - March 28 at 8:30 AMFormer public company CEO now leads RTP firmbizjournals.com - March 20 at 8:28 PMTenax Therapeutics to Present at the 36th Annual Roth Conferenceglobenewswire.com - March 12 at 8:30 AMTenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024globenewswire.com - February 29 at 9:00 AMTenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendanfinance.yahoo.com - February 20 at 9:56 AMTenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendanglobenewswire.com - February 20 at 8:30 AMTENX: First Patient Enrolledfinance.yahoo.com - February 12 at 3:34 PMChapel Hill pharma pushing PHT treatment opens $9M stock offeringbizjournals.com - February 9 at 5:08 PMWhy Tenax Therapeutics (TENX) Stock Is Getting Obliteratedmsn.com - February 8 at 4:05 PMTenax Therapeutics Shares Plummet Premarket After Stock Offeringmarketwatch.com - February 8 at 11:05 AMTenax Therapeutics Announces Pricing Of About $9 Mln Offering Of Shares, Warrants; Stock Tanks 63%markets.businessinsider.com - February 8 at 11:05 AMTenax Therapeutics Announces Pricing of Approximately $9 Million Public Offeringfinance.yahoo.com - February 8 at 11:05 AMWhy Is Tenax Therapeutics (TENX) Stock Down 64% Today?investorplace.com - February 8 at 10:03 AMTenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)finance.yahoo.com - February 8 at 12:17 AMmarketbeat.com - February 7 at 3:29 PMmarketbeat.com - February 7 at 2:14 PMmarketbeat.com - February 7 at 9:59 AMmarketbeat.com - February 7 at 9:48 AMmarketbeat.com - February 7 at 9:42 AMmarketbeat.com - February 7 at 9:32 AMTenax Therapeutics Granted Patent for Heart Treatment Drugsmsn.com - February 7 at 9:17 AMTenax Shares Surge After Acceptance of Patent Applicationmarketwatch.com - February 6 at 2:06 PMTenax surges after patent win for heart failure therapymsn.com - February 6 at 2:06 PMmarketbeat.com - February 6 at 9:46 AMmarketbeat.com - February 6 at 9:34 AMTenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)finance.yahoo.com - February 6 at 9:06 AMTenax Therapeutics Stock (NASDAQ:TENX), Short Interest Reportbenzinga.com - January 3 at 11:27 PMBreakeven On The Horizon For Tenax Therapeutics, Inc. (NASDAQ:TENX)finance.yahoo.com - January 3 at 1:26 PMmarketbeat.com - January 3 at 6:06 AMChapel Hill public company shrinks share volume by nearly 99%bizjournals.com - December 29 at 9:02 PMTenax Therapeutics Stock (NASDAQ:TENX) Dividends: History, Yield and Datesbenzinga.com - December 4 at 5:38 PMTENX: IND Clears Way for Phase IIIfinance.yahoo.com - November 20 at 3:11 PMTenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Boardfinance.yahoo.com - November 17 at 1:11 PMWhy Is Tenax Therapeutics (TENX) Stock Up 300% Today?investorplace.com - November 13 at 5:02 PMTenax Therapeutics Shares Double Premarket After FDA Clears IND for TNX-103marketwatch.com - November 13 at 10:17 AMWhy Tenax Therapeutics (TENX) Stock Is Up 100%benzinga.com - November 13 at 10:17 AMTenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023finance.yahoo.com - November 13 at 10:17 AMTenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)finance.yahoo.com - July 19 at 10:24 AMTENX - Tenax Therapeutics, Inc.finance.yahoo.com - July 13 at 9:40 AMTenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Usetmcnet.com - May 31 at 10:27 AMTenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)finance.yahoo.com - May 31 at 10:27 AMTENX: Prioritizing Levosimendanfinance.yahoo.com - May 22 at 1:21 PMTenax Therapeutics Prioritizes Development Of TNX-103 For Heart Failurefinance.yahoo.com - April 12 at 6:36 PMTenax Therapeutics Provides 2023 Business Updatefinance.yahoo.com - April 12 at 1:05 PMTENX: Patents Guide the Wayfinance.yahoo.com - April 5 at 10:43 AMTENX Tenax Therapeutics, Inc.seekingalpha.com - March 31 at 3:41 PM Get Tenax Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter. Email Address A new way to collect income from stocks (Ad)Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. TENX Media Mentions By Week TENX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TENX News Sentiment▼1.000.33▲Average Medical News Sentiment TENX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TENX Articles This Week▼10▲TENX Articles Average Week Get Tenax Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Protagenic Therapeutics News Adial Pharmaceuticals News Clever Leaves News Trevena News Cadrenal Therapeutics News Can-Fite BioPharma News eFFECTOR Therapeutics News Kineta News Pasithea Therapeutics News Enveric Biosciences News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TENX) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenax Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
